HealthRX.com · Printable coverage checklist
Thymosin alpha peptide and MOTS-c access and cost checklist
Use this sheet before asking a pharmacy, prescriber or insurer about thymosin alpha peptide or MOTS-c. Neither peptide has an FDA-approved US product, so bring these notes to every cost or access conversation.
Gather before the visit or call
Neither peptide has an FDA-approved US product. Keep written answers from each source.
- Confirm which peptide is being discussed: thymosin alpha peptide or MOTS-c
- Note that neither peptide has an FDA-approved US product
- Bring any written prescription or compounding order you have received
- Write down the pharmacy name and whether it is state-licensed or an outsourcing facility
- Check with the pharmacy whether the MOTS-c offer is for the acetate form only
- Note the route of injection the pharmacy plans to use
- Ask the pharmacy to put any certificate of analysis request in writing
- Bring the name of your insurance plan and member card
Access details to record
Write only what you were told. Leave blank if unknown.
Peptide being consideredThymosin alpha peptide or MOTS-c
Pharmacy or clinic name
Pharmacy licence typeState-licensed pharmacy, outsourcing facility or other
Reason for considering this peptideWrite the decision in your own words
Questions to ask the pharmacy, prescriber or insurer
- Is this pharmacy state-licensed or an FDA-registered outsourcing facility?
- Can you name the manufacturer of the peptide ingredient you would use?
- Can you provide a certificate of analysis for the batch you would supply?
- Will my insurance cover this peptide in any form?
- Has any published human study of this peptide been shared with you?
- Can you confirm in writing that this peptide is not FDA-approved?
- Did the October draft HHS policy change your answer on MOTS-c?
- Is there any legal way to obtain a thymosin alpha peptide product sold abroad?
Cost and access tracker
Record only what each source tells you by phone or in writing.
| Date | Source | Price quoted | Answer on access |
|---|---|---|---|